Bladder Preservation in Octogenarians With Invasive Bladder Cancer

被引:14
|
作者
Wehrberger, Clemens [1 ]
Berger, Ingrid [1 ]
Marszalek, Martin [1 ]
Ponholzer, Anton [1 ]
Wehrberger, Marlies [1 ]
Rauchenwald, Michael [1 ]
Madersbacher, Stephan [1 ]
机构
[1] Donauspital, Dept Urol & Androl, A-1220 Vienna, Austria
关键词
RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; ELDERLY-PATIENTS; CARCINOMA; SURVIVAL; EXPERIENCE; MORTALITY; YOUNGER;
D O I
10.1016/j.urology.2009.10.027
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To analyze mortality and morbidity of octogenarians with newly diagnosed invasive transitional cell cancer (TCC) of the bladder who were managed without cystectomy. METHODS Retrospective chart review of all patients with newly diagnosed invasive TCC (>= pT1) in the period of 1997-2007, who were 80 years or older at diagnosis. RESULTS A total of 71 patients (86 + 4 years, mean + standard deviation [SD], pT1: n = 29; >pT2: n = 42) entered this analysis. In this geriatric population, treatment regimens were highly individualized. After transurethral resection, 61% of pT1-patients received bacillus Calmette-Guerin and 62% of those with >pT2-tumors external beam radiation. Mean overall survival (OS) of the entire cohort (n = 71) was 22 + 26 months for pT1-patients 34 + 33 versus 14 + 15 months for those with >pT2-tumors (P = .001). Mean cancer-specific survival was 58 months for pT1-patients and 11 months for >= pT2-patients (P < .001). OS was correlated to tumor stage and the degree of mobility, to a lesser extent to the American Society of Anesthesiologists (ASA) score, and only marginally to chronologic age. Satisfactorily bladder function was preserved in 73%. pT1-patients spent 16% of their remaining life-span in the hospital compared with 23% for patients with >pT2-tumors. CONCLUSIONS OS in TCC is dependent on tumor stage, age, mobility, and comorbidities, and a risk-stratified management is necessary. Patients with pT1G3 tumor and low ASA score have satisfying OS with bladder preservation, but in patients with >= pT2 and ASA 3-4 the prognosis is very bad. It remains questionable whether patients with tumor stages >= pT2 and ASA 1-2 despite high age would benefit from radical cystectomy. UROLOGY 75: 370-375, 2010. (C) 2010 Elsevier Inc.
引用
收藏
页码:370 / 375
页数:6
相关论文
共 50 条
  • [31] Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer
    Buchser, David
    Zapatero, Almudena
    Rogado, Jacobo
    Talaya, Marisol
    Martin de Vidales, Carmen
    Arellano, Ramon
    Bocardo, Gloria
    Cruz Conde, Alfonso
    Perez, Leopoldo
    Murillo, Maria T.
    UROLOGY, 2019, 124 : 183 - 189
  • [32] Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy
    Smith, Zachary L.
    Christodouleas, John P.
    Keefe, Stephen M.
    Malkowicz, S. Bruce
    Guzzo, Thomas J.
    BJU INTERNATIONAL, 2013, 112 (01) : 13 - 25
  • [33] ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder
    Gakis, Georgios
    Efstathiou, Jason
    Lerner, Seth P.
    Cookson, Michael S.
    Keegan, Kirk A.
    Guru, Khurshid A.
    Shipley, William U.
    Heidenreich, Axel
    Schoenberg, Mark P.
    Sagaloswky, Arthur I.
    Soloway, Mark S.
    Stenzl, Arnulf
    EUROPEAN UROLOGY, 2013, 63 (01) : 45 - 57
  • [34] Radical cystectomy and perioperative chemotherapy in octogenarians with bladder cancer
    Savin, Ziv
    Herzberg, Haim
    Schreter, Eran
    Ben-David, Reuben
    Bar-Yosef, Yuval
    Sofer, Mario
    Beri, Avi
    Yossepowitch, Ofer
    Mano, Roy
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (09): : E465 - E470
  • [35] Editorial: Bladder preservation options for bladder cancer
    Davis, Nancy B.
    Kilari, Deepak
    Kessler, Elizabeth R.
    Smelser, Woodson W.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [36] Can p53 help select patients with invasive bladder cancer for bladder preservation?
    Herr, HW
    Bajorin, DF
    Scher, HI
    Cordon-Cardo, C
    Reuter, VE
    JOURNAL OF UROLOGY, 1999, 161 (01) : 20 - 22
  • [37] Organ preservation in muscle-invasive urothelial bladder cancer
    Niglio, Scot A.
    Purswani, Juhi M.
    Schiff, Peter B.
    Lischalk, Jonathan W.
    Huang, William C.
    Murray, Katie S.
    Apolo, Andrea B.
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (03) : 155 - 163
  • [38] Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer
    Maarouf, Aref M.
    Khalil, Salem
    Salem, Emad A.
    ElAdl, Mahmoud
    Nawar, Nashwa
    Zaiton, Fatma
    BJU INTERNATIONAL, 2011, 107 (10) : 1605 - 1610
  • [39] Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
    Koga, Fumitaka
    Takemura, Kosuke
    Fukushima, Hiroshi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (09)
  • [40] Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer
    Turgeon, Guy-Anne
    Souhami, Luis
    Cury, Fabio L.
    Faria, Sergio L.
    Duclos, Marie
    Sturgeon, Jeremy
    Kassouf, Wassim
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 326 - 331